Home > Boards > US Listed > Biotechs >

CORVUS PHARMACEUTICALS (CRVS)

CRVS RSS Feed
Add CRVS Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/6/2022 8:05:24 PM - Followers: 18 - Board type: Free - Posts Today: 0




https://www.corvuspharma.com/

https://www.phillyvoice.com/temple-covid19-immunotherapy-clinical-trial-corvus-coronavirus-research/

https://clinicaltrials.gov/ct2/show/NCT04464395?type=Intr&cond=COVID-19&sort=nwst&draw=2
 

July 7, 2020 09:36 AM ET (BZ Newswire) -- News

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) are "" rel="nofollow ugc" target="_blank">https://www.benzinga.com/pre-market-outlook/20/07/16530313/18-healthcare-stocks-moving-in-tuesdays-pre-market-session"; rel="nofollow ugc">advancing strongly Tuesday following an announcement concerning its foray into COVID-19 treatment.

What Happened: The Burlingame, California-based company said the FDA has reviewed and accepted its investigational new drug application for initiating a COVID-19 study. Accordingly, the company said it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.

The company said it's studying an agonistic humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer.

CPI-006, according to the company, has demonstrated binding to various immune cells and the inducement of a humoral adaptive immune response – B cell activation and lymphocyte trafficking leading to the production of antigen-specific immunoglobulin antibodies.

It has also led to increased levels of memory B cells, which are the cells responsible for long-term immunity, it added.

The company said these may provide immediate and long-term clinical benefits, including shortened recovery time and improved long-term protective immunity, for patients infected by SARS-CoV-2, the virus that causes COVID-19.

What's Next: Corvus expects to enroll up to 30 COVID-19 patients with mild to moderate symptoms in the Phase 1 study, with the patients receiving a single dose of CPI-006, with levels of 0.3, 1, 3 and 5 mg/kg, escalating in four cohorts as the study progresses.

The primary efficacy endpoint is the change in serum immunoglobulin anti-SARS-CoV-2 levels compared to baseline at day 28.
The study also will examine the safety and other clinical endpoints, including time to resolution of symptoms and duration of hospitalization.

The company expects to report data from the study later this year.

If the study meets its objectives, Corvus said it intends to work with the FDA to initiate a broader, randomized study at a fixed dose of CPI-006 that could potentially be adapted into a pivotal study to support a regulatory submission for FDA approval.

Shares were rallying 85.04% to $5.07

 


 
CRVS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CRVS News: H.C. Wainwright Thinks Corvus Pharmaceuticals’ Stock is Going to Recover 05/11/2022 02:26:28 AM
CRVS News: Corvus Pharmaceuticals Provides Program Updates at R&D Symposium 05/10/2022 03:30:00 AM
CRVS News: Securities Registration: Employee Benefit Plan (s-8) 05/05/2022 01:08:16 PM
CRVS News: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results 05/05/2022 12:05:00 PM
CRVS News: Mizuho Securities Sticks to Its Hold Rating for Corvus Pharmaceuticals (CRVS) 05/03/2022 10:15:50 AM
PostSubject
#201   Could shoot to $4,6 or 8 a share diversified holdings 04/06/22 08:05:24 PM
#200   Looking for a nice run here. Setting up nicely! diversified holdings 04/06/22 08:03:58 PM
#199   Wow, 4 month of no posts to the diversified holdings 03/23/22 08:27:24 PM
#198   Volume kicked in late in the day, nice BooDog 11/30/21 04:43:33 PM
#197   Watching closer. 3.28 BooDog 11/30/21 12:53:16 PM
#196   Could be a conspiracy.. gene_genome 10/11/21 02:34:04 PM
#195   News leak..News leak.. gene_genome 10/11/21 02:28:47 PM
#194   And the selling continues as I thought it BooDog 10/02/21 11:06:36 AM
#193   Thinking this is the reset many have been BooDog 09/30/21 01:22:48 PM
#192   Nice rip masterofdisaster 09/27/21 09:55:13 AM
#191   There Is more to this story that none masterofdisaster 09/25/21 09:52:58 AM
#190   From this week's Barron's..pg M7.. gene_genome 09/25/21 09:30:52 AM
#189   OrbiMed Advisors lowered its position in the biopharmaceutical gene_genome 09/25/21 09:19:20 AM
#188   Heavy shorting. The last 3 trading sessions have masterofdisaster 09/24/21 04:51:14 PM
#187   Theres more buys then sell yet this is Roadtojourney 09/24/21 02:17:45 PM
#186   CRVS is not dead masterofdisaster 09/23/21 01:30:52 PM
#185   Did you see the amount of large buys masterofdisaster 09/23/21 07:37:16 AM
#184   Good info thank you masterofdisaster 09/23/21 07:20:23 AM
#183   Here's their form 13 showing what they have BooDog 09/23/21 07:19:08 AM
#182   That was an institutional sale at market not masterofdisaster 09/23/21 07:00:55 AM
#181   Not a good sign masterofdisaster 09/23/21 06:57:45 AM
#180   Insiders taking advantage of the surge... BooDog 09/23/21 06:45:16 AM
#179   For anyone that doesn't know, this is outrageous jxphilli 09/22/21 07:57:11 PM
#178   Good to go. Numbers line up. My bookmark jxphilli 09/22/21 07:51:18 PM
#177   Today's volume numbers Total volume= 14,483,940 shares Short exempts = masterofdisaster 09/22/21 07:00:40 PM
#176   Did you see order flow distribution for today? masterofdisaster 09/22/21 06:54:15 PM
#175   4.2 million short exempts in the last 4 masterofdisaster 09/22/21 06:04:51 PM
#174   550,000 short exempts today on a day where masterofdisaster 09/22/21 06:02:08 PM
#173   Shorts wasted their time shorting this today masterofdisaster 09/22/21 05:08:27 PM
#172   There's no way this should be red. Fukery jxphilli 09/22/21 05:00:35 PM
#171   LET THIS SINK IN ABOUT TODAYS TRADINGhttps://investorshub.advfn.com/uimage/uploads/2021/9/22/BR masterofdisaster 09/22/21 04:54:39 PM
#170   Shorts went to town today!!! You need to masterofdisaster 09/22/21 03:35:42 PM
#169   MMs have taken the day off and let masterofdisaster 09/22/21 02:54:59 PM
#168   CRVS is holding up well today. masterofdisaster 09/22/21 11:59:52 AM
#167   Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs gene_genome 09/22/21 10:37:02 AM
#166   Tang Capital Partners Lp Reports 8.8% Passive Stake gene_genome 09/22/21 10:35:31 AM
#165   Holding up well. The last 2 days we masterofdisaster 09/22/21 10:32:48 AM
#164   Daily short exempt numbers are ridiculous masterofdisaster 09/22/21 09:31:37 AM
#163   Some think it is for the cancer treatment masterofdisaster 09/22/21 09:25:58 AM
#162   is this good? Surfacetite 09/22/21 09:22:24 AM
#161   25,000 available now masterofdisaster 09/22/21 08:38:36 AM
#160   50,000 available. A small fraction of what the masterofdisaster 09/22/21 08:12:01 AM
#159   85,000 shares available on fintel at a very masterofdisaster 09/22/21 07:36:21 AM
#158   I think today is going to be wild masterofdisaster 09/22/21 06:48:46 AM
#157   Thanks for the info masterofdisaster 09/21/21 07:17:45 PM
#156   "CRVS (NASDAQ:CRVS), we notice a call option trade gene_genome 09/21/21 07:12:42 PM
#155   2 million short exempts today! This is insane masterofdisaster 09/21/21 05:47:17 PM
#154   $10+ soon!$$$ Jess070283 09/21/21 03:36:24 PM
#153   Appreciate the insight spindog 09/21/21 03:36:08 PM
#152   Honestly it looks like an unsustainable move and masterofdisaster 09/21/21 03:33:35 PM
PostSubject
Consent Preferences